查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2034917

全球人工心臟替代裝置市場：市場規模、佔有率和趨勢分析（2026-2032 年）

Artificial Heart Replacement Device Market Size, Share & Trends Analysis | Global | 2026-2032
出版日期: | 出版商: iData Research Inc. | 英文 61 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球人工心臟替代裝置市場報告（至2032年）

2025年全球人工心臟替代設備市場規模為1,180萬美元。預計到2032年，該市場將以0.21%的複合年成長率成長，達到1,200萬美元。

本報告涵蓋全球人工心臟替代裝置市場，包括替代心臟下心室並恢復血液循環的機械裝置。

分析內容包括銷售量、平均售價 (ASP)、治療次數、市場規模、市場佔有率、成長趨勢、到 2032 年的市場預測以及到 2022 年的歷史數據。

市場成長主要得益於FDA核准50cc全心臟置換術(TM)、未來可能核准作為終末治療方案以及有利的健保報銷政策。然而，來自心室輔助裝置的競爭以及永久性心臟置換方案的缺乏仍然限制了市場的進一步擴張。

市場概覽

全球人工心臟替代裝置市場包括用於替代心臟下心室的機械裝置。人工心臟植入後，可執行泵血功能，並支持全身血液循環。

目前，人工心臟主要用作過渡治療，直到可以進行心臟移植。其設計目的是穩定患者病情，維持其健康，直至在沒有其他合適選擇的情況下，患者能夠接受捐贈心臟。

這是心臟外科醫療設備市場中一個相對早期的細分領域。該市場的特點是持續的研發和臨床評估，製造商專注於產品的耐用性、生物相容性和改善患者的生活品質。

預計多種新型心臟輔助裝置將繼續在全球主要地區推動臨床試驗和監管核准流程。然而，由於符合條件的患者數量較少、來自心室輔助裝置（VAD）的競爭以及缺乏廣泛應用的永久性人工心臟替代裝置，這些裝置的普及應用仍然有限。

市場促進因素

FDA核准50cc人工心臟

2020 年 3 月，FDA核准50cc 全心臟置換 (TM) 作為移植等待名單上的設備，擴大了符合人工心臟置換條件的患者群體。

這款50cc的裝置適用於體型較小的患者，他們可能不適合植入傳統的70cc全心臟置換（TM）裝置。這對於以往人工心臟選擇有限的女性和青少年來說尤其重要。

透過擴大適用人群，50cc 的人工心臟裝置將惠及患者群體較小的患者，從而促進患者群體有限的細分市場的成長。由於人工心臟置換術仍然是一個低銷量、高度專業化的市場，即使適應症的略微擴展也會產生重大影響。

FDA核准人工心臟用於臨終關懷

末期治療為人工心臟替代裝置市場帶來了潛在的成長機會。 SynCardia公司於2014年12月核准用於終末期治療的全心臟替代裝置（TM）的研究，並獲得臨床實驗醫療設備豁免。

如果核准用於末期治療，人工心臟將用於治療不太可能接受心臟移植的一組新患者。這將使潛在患者群體擴大到除移植過渡病例之外的其他患者。

如果人工心臟核准並被採納為最終治療方案，它們可以幫助那些患有不可逆性雙心室衰竭且需要長期支持的患者。這將拓展其臨床應用範圍，並促進未來市場成長。

有利的贖回

有利的報銷條款仍然是市場發展的關鍵促進因素。美國醫療保險和醫療補助服務中心（CMS）指出，對於患有不可逆性雙心室衰竭的患者，全人工心臟發揮其他任何機械循環支持裝置都無法替代的作用。

為患者植入人工心臟的醫院將獲得與心臟移植手術同等的補償，外加最高 53,000 美元的新技術補助。這意味著患者出院後，醫院最多可獲得 345,000 美元的人工心臟手術補償。

這種報銷機制不僅能充分覆蓋設備成本，還能提高醫院進行手術的經濟可行性。只要報銷政策維持有利，市場接受度就會持續提升。

市場限制

VAD市場

心室輔助裝置（VAD）與人工心臟爭奪相似的患者群體。過渡性VAD的作用與人工心臟類似，都是在心臟移植前提供臨時支持；而臨終關懷VAD的作用與人工心臟類似，都是提供長期支持。

一個主要區別在於，用人工心臟取代心臟需要切除部分或全部活體心臟。這使得活體心臟無法恢復功能。相較之下，心室輔助裝置（VAD）並非替換活體心臟，而是輔助其運作。

雖然人工心臟可能對某些患有不可逆性雙心室衰竭的患者俱有顯著優勢，但靜脈通路裝置（VAD）仍然是其主要的競爭技術。只要VAD和人工心臟繼續爭奪重疊的患者群體，VAD就可能繼續阻礙人工心臟市場的成長。

缺乏永久性心臟替代療法

缺乏永久性人工心臟替代方案仍是一大限制因素。首例AbioCor®人工心臟移植手術於2009年進行，但患者約一個月後過世。

自那次手術後，Abiomed公司未再進行任何植入手術，並將業務重心轉移到其他領域。這導致市場上永久性人工心臟替代裝置短缺，原因之一是Abiomed公司未進行此類手術。

由於缺乏廣泛應用的永久性心臟移植方案，市場仍主要集中於移植前的過渡治療。這限制了銷售量，也阻礙了市場覆蓋更廣泛的末期患者群體。

有限的商業規模

與其他心臟外科手術器械領域相比，人工心臟置換器械市場規模仍然小規模。目標患者群體有限，需要先進的臨床技術、醫院基礎設施以及與移植中心的合作。

即使有臨床需要，人工心臟置換術也不是常規手術。患者選擇標準非常嚴格，許多潛在患者最終會接受心室輔助裝置（VAD）或其他機械循環支持裝置的治療。

這種有限的商業規模限制了市場成長。由於目前應用主要集中在特定設施和特殊用途領域，製造商必須繼續投資於研發、法規遵循和臨床證據。

市場覆蓋範圍和數據範圍

  • 量化範圍：市場規模、市場佔有率、手術數量、市場預測、市場成長率、銷售單位數量、平均售價。
  • 定性範圍：市場促進因素和阻礙因素、競爭分析、近期併購、公司簡介、產品系列和主要競爭對手。
  • 目標時期：基準年為 2025 年，預測至 2032 年，歷史資料截至 2022 年。
  • 建立市場模型：收入分析採用銷售量和平均售價（ASP），並輔以治療量、競爭市場佔有率分析和預測假設。
  • 目標設備：本報告重點關注人工心臟替代裝置，該裝置替代心臟的下心室並執行泵血功能。這些裝置主要用作等待心臟移植患者的臨時解決方案。

目標市場及區隔

人工心臟置換設備市場

本報告涵蓋了全球人工心臟替代設備市場，將其作為心臟外科手術和機械循環支援 (MCS) 領域的一個專門細分市場。

人工心臟替代裝置是一種機械裝置，旨在取代心臟下心室的泵血功能。這些裝置用於治療嚴重雙心室衰竭患者，通常用作心臟移植的過渡治療。

此市場分析依據市場規模、市場佔有率、治療次數、市場預測、市場成長率、銷售量及平均售價。

本報告根據病患資格標準、作為移植過渡手段的用途、作為最終治療手段的潛力、報銷條件、臨床試驗趨勢、監管核准流程以及與 VAD（心室輔助裝置）技術的競爭情況來評估需求。

這種配置有助於製造商、投資者和策略團隊了解人工心臟置換在治療晚期心臟衰竭中的地位，以及隨著新設備和適應症的開發，市場將如何變化。

競爭分析

SynCardia 仍然是全球人工心臟替代市場的領導者。其全可更換人工心臟™是首個獲得美國 FDA核准的人工心臟，目前已在美國和加拿大上市。

除了上述市場外，該設備已在全球超過27個國家的特定病例和臨床試驗中植入使用。預計SynCardia將在整個預測期內保持全球顯著的市場佔有率。

然而，隨著其他地區競爭對手的新型人工心臟設備獲得監管部門的核准，SynCardia 的長期壟斷地位預計將逐漸削弱。

CARMAT 憑藉其 Aeson® 全心臟，預計將在 2025 年成為人工心臟設備市場第二大競爭對手。 Aeson 系統專為末期雙心室心臟衰竭患者設計，主要用作移植前的過渡方案，而不是永久性替代療法。

Aeson的設備已獲得歐洲CE核准，並在部分醫療機構為少數患者植入，使CARMAT公司擁有了小規模但穩固的商業性地位。儘管CARMAT的技術具有差異化優勢，但仍面臨財務和營運方面的挑戰，最終在2025年進行了法院監督下的重組，將其資產和營運轉移至一家新成立的營業單位，以支持其繼續研發和有限的商業化。

技術與臨床實務的趨勢

用作移植前的過渡手段

人工心臟替代裝置的主要臨床作用仍是彌合心臟移植前的這段空檔期。這些裝置有助於穩定患者的病情，直到他們等待合適的捐贈心臟。

對於患有嚴重雙心室衰竭、可能無法從其他機械循環支持裝置中獲得足夠支持的患者來說，這一作用尤其重要。

適用於小型患者

50cc 全心臟置換術™擴大了適用範圍，使體型較小的患者，包括女性和青少年，也能接受手術。這是一項重大進步，因為先前體型限制曾仿單標示外一些患者無法接受手術。

在手術數量有限的市場中，較小的設備選擇可以幫助擴大可治療的患者範圍。

具有作為永久性治療方案的潛力

末期治療仍將是重要的市場機會。如果人工心臟用於不適合移植的患者獲得核准，市場範圍可能會從移植前的臨時「過渡」用途擴展到更廣泛的領域。

然而，這一機會取決於臨床證據、監管部門的核准、長期安全性和設備耐用性。

提高耐久性和生物相容性

製造商正投資研發旨在提高耐用性和生物相容性的新一代設計。這些改進對於延長使用壽命、減少併發症和提高患者的生活品質至關重要。

這些領域的進展有望影響市場從特定患者群體擴展到多大程度。

數量有限

它們的市場供應仍然有限。 SynCardia在北美市場已相當成熟，但CARMAT僅在歐洲少數醫療機構提供。

更廣泛的應用取決於監管進展、生產穩定性、臨床可靠性和醫院準備。

與VAD的競爭

心室輔助裝置（VAD）仍然是主要的競爭技術。 VAD可以幫助那些在心臟移植前需要過渡治療或安寧療護的患者，同時也能保留活體心臟。

對於使用心室輔助裝置 (VAD) 的患者，尤其是患有不可逆性雙心室衰竭的患者，人工心臟必須展現明顯的價值。

地區

本報告涵蓋全球調查區域，包括北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

這份報告的意義

  • 目前全球人工心臟替代設備市場規模有多大？預計到 2032 年將成長多少？
  • 銷售量、治療量、平均售價（ASP）和市場價值如何隨時間變化？
  • 人工心臟在心臟移植前的過渡治療中扮演什麼角色？
  • 50cc 全心臟置換術 (TM) 如何擴大體型較小患者的適應症範圍？
  • 「目的地療法」核准可能會對市場產生哪些潛在影響？
  • 不同的醫療報銷政策對人工心血管手術的發展產生了哪些影響？
  • 為什麼心室輔助裝置（VAD）仍然是主要的競爭技術？
  • 哪些因素限制了永久性人工心臟替代裝置的發展？
  • 全球人工心臟替代設備市場的主要企業有哪些？
  • SynCardia 和 CARMAT 在競爭格局中處於什麼位置？

iData Research 的《全球人工心臟替代設備市場報告》透過設備層面的分析、基於手術流程的建模、平均售價 (ASP) 數據、企業市場占有率分析以及到 2032 年的預測來解答這些問題。本報告可用於評估需求、比較競爭對手、了解人工心臟發展趨勢，並幫助您制定全球人工心臟替代設備市場的產業計畫。

目錄

調查方法

  • 第一步：專案啟動與團隊組建
  • 步驟 2：準備資料系統並進行二次調查。
  • 步驟 3：設計和準備訪談和調查問卷。
  • 第四步：進行初步調查
  • 第五步：調查與分析：建立基準估計值
  • 第六步：市場預測與分析
  • 步驟 7：辨識策略機遇
  • 步驟 8：最終審核和市場推廣
  • 步驟九：客戶回饋與市場監測

全球關稅的影響

人工心臟置換設備市場

  • 執行摘要
    • 全球人工心臟置換裝置市場概覽
    • 競爭分析
    • 目標程式
    • 目標區域
  • 介紹
  • 手術次數
  • 市場分析與預測
  • 促進因素和抑制因素
  • 競爭性市佔率分析

附錄

Product Code: iDATA_GLCS26_AHR_MC

Global Artificial Heart Replacement Device Market Report to 2032

The global artificial heart replacement device market was valued at $11.8 million in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 0.21%, reaching $12 million by 2032.

This report covers the global market for artificial heart replacement devices, including mechanical devices that replace the lower chambers of the heart and restore blood circulation.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by FDA approval of the 50cc Total Artificial Heart(TM), potential destination therapy approval, and favorable reimbursement. However, competition from ventricular assist devices and the lack of permanent artificial heart replacement options continue to limit stronger market expansion.

Market Overview

The global artificial heart replacement device market includes mechanical devices that replace the lower chambers of the heart. Once implanted, the artificial heart takes over the pumping function and supports blood circulation throughout the body.

Artificial hearts are currently used primarily as temporary bridge-to-transplant solutions. They are designed to keep patients stable and healthy enough to receive a donor heart when no other suitable option is available.

This is a relatively early-stage segment within the cardiac surgery device market. The market is characterized by ongoing research, development, and clinical evaluation, with manufacturers working to improve durability, biocompatibility, and patient quality of life.

Multiple devices are expected to continue moving through clinical trials and regulatory pathways across key global regions. However, adoption remains limited due to the small eligible patient population, competition from VADs, and the lack of broadly available permanent artificial heart replacement devices.

Market Drivers

FDA Approval of 50cc Artificial Heart

The FDA approval of the 50cc Total Artificial Heart(TM) as a bridge-to-transplant device in March 2020 expanded the eligible patient population for artificial heart replacement.

The 50cc device is suitable for patients with smaller body frames who may not fit the traditional 70cc Total Artificial Heart(TM). This is especially important for women and adolescents, who may have previously had fewer artificial heart options.

By broadening access to smaller patients, the 50cc device supports market growth in a segment with a narrow patient base. Even modest expansion in eligibility can be meaningful because artificial heart replacement remains a low-volume, highly specialized market.

FDA Approval of Artificial Heart for Destination Therapy

Destination therapy represents a potential growth opportunity for the artificial heart replacement device market. SynCardia's investigational device exemption application to study the Total Artificial Heart(TM) for destination therapy was approved in December 2014.

Approval for destination therapy would allow artificial hearts to be used in a new cohort of patients who are not expected to receive a heart transplant. This would expand the potential patient population beyond bridge-to-transplant cases.

If artificial hearts become approved and adopted for destination therapy, they could serve patients with irreversible biventricular failure who need long-term support. This would create a broader clinical role and support future market expansion.

Favorable Reimbursement

Favorable reimbursement remains an important market driver. The Centers for Medicare and Medicaid Services has stated that the Total Artificial Heart fulfills a role that no other mechanical circulatory support device can for patients with irreversible biventricular failure.

Hospitals implanting artificial hearts are reimbursed at the same rate as a heart transplant, plus up to $53,000 more through new technology add-ons. This means hospitals can earn up to $345,000 for an artificial heart procedure after patient discharge.

This reimbursement structure more than covers the cost of the device and makes procedures more economically feasible for hospitals. As long as reimbursement policies remain favorable, they will continue to support market adoption.

Market Limiters

VAD Market

Ventricular assist devices compete with artificial hearts for a similar patient population. Bridge-to-transplant VADs serve a similar temporary support role, while destination therapy VADs serve a similar long-term support role.

One major difference is that artificial heart replacement requires part or all of the natural heart to be removed. This eliminates the chance of native heart recovery. VADs, by contrast, assist the natural heart rather than replacing it.

Although artificial hearts may offer important benefits in certain patients with irreversible biventricular failure, VADs remain a major competing technology. As long as VADs and artificial hearts compete for overlapping patient groups, VADs will continue to limit artificial heart market growth.

Lack of Permanent Artificial Heart Replacements

The lack of permanent artificial heart replacement options remains a major limiter. In 2009, the first AbioCor(R) implant was performed, but the patient passed away approximately one month afterward.

Since that procedure, Abiomed has not performed additional implants and has shifted its focus to other segments. This absence has contributed to the lack of permanent artificial heart replacement devices in the market.

Without broadly available permanent artificial heart options, the market remains focused mainly on bridge-to-transplant therapy. This limits unit sales and prevents the market from reaching a larger destination therapy population.

Limited Commercial Scale

The artificial heart replacement device market remains very small compared with other cardiac surgery device segments. It serves a narrow patient group and requires specialized clinical expertise, hospital infrastructure, and transplant-center coordination.

Even when clinical need exists, artificial heart replacement is not a routine procedure. Patient selection is highly specific, and many potential patients may be treated with VADs or other mechanical circulatory support devices.

This limited commercial scale constrains market growth. Manufacturers must continue investing in research, regulatory work, and clinical evidence while adoption remains concentrated in select centers and specialized use cases.

Market Coverage and Data Scope

  • Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
  • Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
  • Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
  • Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
  • Device scope: The report covers artificial heart replacement devices that replace the lower chambers of the heart and take over blood pumping function, primarily as a temporary solution for patients awaiting heart transplantation.

Markets Covered and Segmentation

Artificial Heart Replacement Device Market

The report covers the global artificial heart replacement device market as a dedicated segment within cardiac surgery and mechanical circulatory support.

Artificial heart replacement devices are mechanical devices designed to replace the pumping function of the lower chambers of the heart. These devices are used in patients with severe biventricular failure, most often as a bridge to heart transplantation.

The market is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

The report evaluates demand based on patient eligibility, bridge-to-transplant use, destination therapy potential, reimbursement conditions, clinical trial activity, regulatory pathways, and competition from VAD technologies.

This structure helps manufacturers, investors, and strategy teams understand how artificial heart replacement fits within advanced heart failure treatment and how the market may evolve as new devices and indications develop.

Competitive Analysis

SynCardia remains the leading company in the global artificial heart replacement market. Its Total Artificial Heart(TM) was the first total artificial heart to receive U.S. FDA approval and is commercially available in both the United States and Canada.

Beyond these markets, the device has been implanted in select cases and clinical studies across more than 27 countries worldwide. SynCardia is expected to retain a significant share of the global market over the forecast period.

However, SynCardia's long-standing monopoly is expected to gradually diminish as additional total artificial heart devices from competing manufacturers receive regulatory approval in other regions.

CARMAT was the second-leading competitor in the artificial heart device market in 2025, supported by its Aeson(R) total artificial heart. The Aeson system is intended for patients with end-stage biventricular heart failure and is used mainly as a bridge-to-transplant solution rather than permanent replacement therapy.

The Aeson device received CE Mark approval in Europe and has been implanted in a limited number of patients at selected centers, giving CARMAT a narrow but established commercial presence. Despite its technology differentiation, CARMAT faced financial and operational challenges and entered court-supervised restructuring in 2025, with assets and activities transferred to a new entity to allow continued development and limited commercialization.

Technology and Practice Trends

Bridge-to-Transplant Use

Bridge-to-transplant use remains the main clinical role for artificial heart replacement devices. These devices help keep patients stable while they wait for a donor heart.

This role is especially important for patients with severe biventricular failure who may not be adequately supported by other mechanical circulatory support options.

Smaller-Frame Patient Access

The 50cc Total Artificial Heart(TM) expanded access for smaller-frame patients, including women and adolescents. This is important because size limitations previously restricted eligibility for some patients.

Smaller device options may help broaden the treatable population in a market with limited procedure volumes.

Destination Therapy Potential

Destination therapy remains a major future opportunity. If artificial hearts are approved for use in patients who are not expected to receive a transplant, the market could expand beyond temporary bridge-to-transplant use.

However, this opportunity depends on clinical evidence, regulatory approval, long-term safety, and device durability.

Durability and Biocompatibility Improvements

Manufacturers are investing in next-generation designs aimed at improving durability and biocompatibility. These improvements are needed to support longer use, reduce complications, and improve patient quality of life.

Progress in these areas will influence how far the market can expand beyond highly selected patients.

Limited Commercial Availability

Commercial availability remains limited. SynCardia is established in North America, while CARMAT has a limited presence in Europe through selected centers.

Broader adoption will depend on regulatory progress, manufacturing stability, clinical confidence, and hospital readiness.

Competition from VADs

VADs remain the main competing technology. They can support bridge-to-transplant and destination therapy patients while preserving the natural heart.

Artificial hearts must demonstrate clear value in patients where VADs are insufficient, especially those with irreversible biventricular failure.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

  • How large is the global artificial heart replacement device market today, and how much is it expected to grow through 2032?
  • How are unit sales, procedure numbers, ASPs, and market values changing over time?
  • What role do artificial hearts play in bridge-to-transplant therapy?
  • How does the 50cc Total Artificial Heart(TM) expand eligibility for smaller-frame patients?
  • What is the potential market impact of destination therapy approval?
  • How do reimbursement policies affect hospital adoption of artificial heart procedures?
  • Why do VADs remain a major competing technology?
  • What limits the development of permanent artificial heart replacement devices?
  • Which companies lead the global artificial heart replacement device market?
  • How are SynCardia and CARMAT positioned in the competitive landscape?

The Global Artificial Heart Replacement Device Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand artificial heart development trends, and support commercial planning in the global artificial heart replacement device market.

TABLE OF CONTENT

Research Methodology

  • Step 1: Project Initiation & Team Selection
  • Step 2: Prepare Data Systems And Perform Secondary Research
  • Step 3: Preparation For Interviews & Questionnaire Design
  • Step 4: Performing Primary Research
  • Step 5: Research Analysis: Establishing Baseline Estimates
  • Step 6: Market Forecast And Analysis
  • Step 7: Identify Strategic Opportunities
  • Step 8: Final Review And Market Release
  • Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Artificial Heart Replacement Device Market

  • 20.1 Executive Summary
    • 20.1.1 Global Artificial Heart Replacement Device Market Overview
    • 20.1.2 Competitive Analysis
    • 20.1.3 Procedures Included
    • 20.1.4 Regions Included
  • 20.2 Introduction
  • 20.3 Procedure Numbers
  • 20.4 Market Analysis And Forecast
  • 20.5 Drivers And Limiters
    • 20.5.1 Market Drivers
    • 20.5.2 Market Limiters
  • 20.6 Competitive Market Share Analysis

Appendix

LIST OF CHARTS

  • Chart 20-1: Artificial Heart Replacement Device Market, Global, 2025 & 2032
  • Chart 20-2: Artificial Heart Replacement Device Procedures, Global, 2025
  • Chart 20-3: Artificial Heart Replacement Procedures by Region, Global, 2022 - 2032
  • Chart 20-4: Artificial Heart Replacement Device Market, Global, 2022 - 2032
  • Chart 20-5: Leading Competitors, Artificial Heart Replacement Device Market, Global, 2025

LIST OF FIGURES

  • Figure 20-1: Artificial Heart Replacement Procedures Covered
  • Figure 20-2: Artificial Heart Replacement Device Regions Covered, Global (1 of 2)
  • Figure 20-3: Artificial Heart Replacement Device Regions Covered, Global (2 of 2)
  • Figure 20-4: Artificial Heart Replacement Procedures by Region, Global, 2022 - 2032
  • Figure 20-5: Artificial Heart Replacement Procedures by Country, North America, 2022 - 2032
  • Figure 20-6: Artificial Heart Replacement Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
  • Figure 20-7: Artificial Heart Replacement Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
  • Figure 20-8: Artificial Heart Replacement Procedures by Country, Western Europe, 2022 - 2032
  • Figure 20-9: Artificial Heart Replacement Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
  • Figure 20-10: Artificial Heart Replacement Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
  • Figure 20-11: Artificial Heart Replacement Procedures by Country, Middle East, 2022 - 2032
  • Figure 20-12: Artificial Heart Replacement Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
  • Figure 20-13: Artificial Heart Replacement Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
  • Figure 20-14: Artificial Heart Replacement Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
  • Figure 20-15: Artificial Heart Replacement Procedures by Country, Africa, 2022 - 2032
  • Figure 20-16: Artificial Heart Replacement Device Market, Global, 2022 - 2032
  • Figure 20-17: Units Sold by Region, Artificial Heart Replacement Device Market, Global, 2022 - 2032
  • Figure 20-18: Average Selling Price by Region, Artificial Heart Replacement Device Market, Global, 2022 - 2032 (US$)
  • Figure 20-19: Market Value by Region, Artificial Heart Replacement Device Market, Global, 2022 - 2032 (US$M)
  • Figure 20-20: Leading Competitors, Artificial Heart Replacement Device Market, Global, 2025